Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.71 |
| ▸ | IL6ST | P40189 | 5/20 | 0.41 |
| ▸ | AR | P10275 | 2/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 10/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11949263 | 1.00 | PIK3CD (0.71) | PIK3CDIL6STARSTAT3CYP2D6 | |
| SCHEMBL18576421 | 1.00 | PIK3CD (0.71) | PIK3CDIL6STARSTAT3CYP2D6 | |
| SCHEMBL24983622 | 0.85 | PIK3CD (0.67) | PIK3CDIL6STARSTAT3CYP2D6 | |
| SCHEMBL20697286 | 0.85 | PIK3CD (0.53) | PIK3CDIL6STARSTAT3IDH1 | |
| SCHEMBL13773155 | 0.83 | PIK3CD (1.00) | PIK3CDIL6STSTAT3CYP2D6IDH1 | |
| SCHEMBL13773173 | 0.83 | PIK3CD (1.00) | PIK3CDIL6STSTAT3CYP2D6IDH1 | |
| SCHEMBL2036191 | 0.83 | PIK3CD (0.50) | PIK3CDIL6STARSTAT3IDH1 | |
| SCHEMBL19710602 | 0.82 | PIK3CD (0.73) | PIK3CDIL6STSTAT3CYP2D6IDH1 | |
| SCHEMBL27326397 | 0.81 | PIK3CD (0.49) | PIK3CDIL6STARSTAT3 | |
| SCHEMBL9386402 | 0.81 | PIK3CD (0.61) | PIK3CDIL6STSTAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2020-04-23 | — | — | US | disclosed |
| US-20170137384-A1 | PROCESS FOR THE PREPARATION OF KINASE INHIBITORS AND INTERMEDIATES THEREOF | ALCON INC. (CH) | 2017-05-18 | — | — | US | disclosed |
| US-9643927-B1 | Process for the preparation of kinase inhibitors and intermediates thereof | AERIE PHARMACEUTICALS, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-8232271-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137384-A1 | PROCESS FOR THE PREPARATION OF KINASE INHIBITORS AND INTERMEDIATES THEREOF | MAP3K1, MAP3K6, MAP3K7 | PIK3CD 103/4885IL6ST 3302/4885AR 4536/4885 |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | PIK3CD 1022/4885IL6ST 3447/4885AR 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.